Adrian Gheorghe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adrian Gheorghe has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Kalipso Chalkidou
Global Health and Development, Imperial College London, London, United Kingdom
3 shared publications- Katharina Hauck
MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK
3 shared publications - Melanie Calvert
University of Birmingham
3 shared publications - Sara Valente de Almeida
Department of Infectious Disease Epidemiology, Imperial College London School of Public Health, London, UK
3 shared publications - Thomas Pinkney
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3 shared publications - Abha Mehndiratta
Center for Global Development, Washington, District of Columbia, USA
2 shared publications
Latest Publications
- 30 July 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (1) , 12-17
Re-envisioning the value proposition for investment in cancer care
The place of cancer within broader health system development highlights key contradictions and distortions. Although innovation in cancer care, spanning medicines, artificial intelligence, and radiation therapy, are advancing rapidly, these technologies can be costly and often provide marginal benefits. Lower-cost approaches, such as screening, patient navigation, and supportive care, remain underutilized, especially in developing health systems. Simultaneously, the financial burden of cancer exacerbates inequities, driving patients into poverty and straining under-resourced systems. To address these contradictions, we call for a re-envisioning of cancer care as a strategic investment within health systems by presenting 4 key transitions: (1) a shift in the predominant narrative of cancer control as a clinical problem to positioning it as a universal health system priority, with far-reaching societal and economic benefits; (2) a greater emphasis on how cancer care supports health system strengthening across the full continuum of services involved in cancer control; (3) a view on cancer treatment as a gateway for technology and systemic investments, showcasing the potential to generate and use cross-cutting improvements with benefits across clinical areas; and (4) the need to align cancer control with rigorous fiscal, economic, and operational planning to ensure that investments deliver broad and sustainable health system impacts. By embedding cancer control into health system development, governments can optimize resources, strengthen system resilience and close equity gaps while addressing current and future health challenges.
- 30 July 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (1) , 12-17
Re-envisioning the value proposition for investment in cancer care
The place of cancer within broader health system development highlights key contradictions and distortions. Although innovation in cancer care, spanning medicines, artificial intelligence, and radiation therapy, are advancing rapidly, these technologies can be costly and often provide marginal benefits. Lower-cost approaches, such as screening, patient navigation, and supportive care, remain underutilized, especially in developing health systems. Simultaneously, the financial burden of cancer exacerbates inequities, driving patients into poverty and straining under-resourced systems. To address these contradictions, we call for a re-envisioning of cancer care as a strategic investment within health systems by presenting 4 key transitions: (1) a shift in the predominant narrative of cancer control as a clinical problem to positioning it as a universal health system priority, with far-reaching societal and economic benefits; (2) a greater emphasis on how cancer care supports health system strengthening across the full continuum of services involved in cancer control; (3) a view on cancer treatment as a gateway for technology and systemic investments, showcasing the potential to generate and use cross-cutting improvements with benefits across clinical areas; and (4) the need to align cancer control with rigorous fiscal, economic, and operational planning to ensure that investments deliver broad and sustainable health system impacts. By embedding cancer control into health system development, governments can optimize resources, strengthen system resilience and close equity gaps while addressing current and future health challenges.
- Open Access
- 23 September 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (9) , e015402
Value for money of medicine sampling and quality testing: evidence from Indonesia
Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines’ regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
- 23 September 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (9) , e015402
Open AccessValue for money of medicine sampling and quality testing: evidence from Indonesia
Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines’ regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
- 31 March 2024
- Published by Institutul National de Cercetare Dezvoltare Medico-Militara "Cantacuzino" in Romanian Archives of Microbiology and Immunology
- Vol. 83 (1) , 28-45
THE NATIONAL-LEVEL ECONOMIC BURDEN OF ANTIMICROBIAL RESISTANCE - A REVIEW OF AVAILABLE DATA
Antimicrobial resistance (AMR) has long been acknowledged as a global public health threat with potentially far-reaching economic consequences. However, no previous literature review has focused exclusively on national-level estimates of the AMR economic burden. Four electronic databases were searched for studies published between 01 January 2010 and September 2023 that reported original, national- or supra-national estimates of AMR economic burden. Additionally, reference lists of previous reviews and online reports were searched. Bibliographic and methodological characteristics of the included studies were extracted and summarized narratively. Thirty studies were included, reporting estimates of economic burden for 67 distinct countries combined, most of them high-income. The United States has the richest evidence base, with 13 studies in total. There was significant variation in terms of study designs, comparators, and uncertainty analysis. The overwhelming majority of studies quantified the economic impacts of AMR in terms of direct healthcare costs, with less than half the studies estimating the indirect costs of AMR and only one study estimating non-health economic impacts on trade and poverty. Further efforts are needed to improve the availability of national-level data on infection economics and to produce guidance for capturing the economic burden of AMR if such studies are to be useful to decisionmakers.
- 31 March 2024
- Published by Institutul National de Cercetare Dezvoltare Medico-Militara "Cantacuzino" in Romanian Archives of Microbiology and Immunology
- Vol. 83 (1) , 28-45
THE NATIONAL-LEVEL ECONOMIC BURDEN OF ANTIMICROBIAL RESISTANCE - A REVIEW OF AVAILABLE DATA
Antimicrobial resistance (AMR) has long been acknowledged as a global public health threat with potentially far-reaching economic consequences. However, no previous literature review has focused exclusively on national-level estimates of the AMR economic burden. Four electronic databases were searched for studies published between 01 January 2010 and September 2023 that reported original, national- or supra-national estimates of AMR economic burden. Additionally, reference lists of previous reviews and online reports were searched. Bibliographic and methodological characteristics of the included studies were extracted and summarized narratively. Thirty studies were included, reporting estimates of economic burden for 67 distinct countries combined, most of them high-income. The United States has the richest evidence base, with 13 studies in total. There was significant variation in terms of study designs, comparators, and uncertainty analysis. The overwhelming majority of studies quantified the economic impacts of AMR in terms of direct healthcare costs, with less than half the studies estimating the indirect costs of AMR and only one study estimating non-health economic impacts on trade and poverty. Further efforts are needed to improve the availability of national-level data on infection economics and to produce guidance for capturing the economic burden of AMR if such studies are to be useful to decisionmakers.
- Open Access
- 8 March 2024
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 30 (Suppl 2) , s3-s7
Measuring progress in institutionalising evidence-informed priority-setting in the Indian healthcare system: an application using the iProSE scale
Faced with the recovery from COVID-19, debt, increasing effects of climate change and global macroeconomic uncertainty, many governments in low-income and middle-income countries (LMICs) are likely to have less money to spend on healthcare in real terms up to 2030 compared with what they had before COVID-19.1 2 As such, already resource-constrained health systems will have to do more with less if hard-earned progress in improving health and financial risk protection is not to be lost. Using evidence to inform healthcare priority-setting has long been recognised as central to making progress towards universal health coverage,3 and seems more important than ever today. Evidence-informed priority-setting (EIPS), understood as a form of systematic priority-setting that involves the explicit consideration of evidence to determine the healthcare interventions to be provided,4 is not just sensible in theory; recent empirical evidence suggests that EIPS represents good value for money, for example, in Thailand, EIPS delivered an estimated 8:1 return on investment (ROI).5
- 8 March 2024
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 30 (Suppl 2) , s3-s7
Open AccessMeasuring progress in institutionalising evidence-informed priority-setting in the Indian healthcare system: an application using the iProSE scale
Faced with the recovery from COVID-19, debt, increasing effects of climate change and global macroeconomic uncertainty, many governments in low-income and middle-income countries (LMICs) are likely to have less money to spend on healthcare in real terms up to 2030 compared with what they had before COVID-19.1 2 As such, already resource-constrained health systems will have to do more with less if hard-earned progress in improving health and financial risk protection is not to be lost. Using evidence to inform healthcare priority-setting has long been recognised as central to making progress towards universal health coverage,3 and seems more important than ever today. Evidence-informed priority-setting (EIPS), understood as a form of systematic priority-setting that involves the explicit consideration of evidence to determine the healthcare interventions to be provided,4 is not just sensible in theory; recent empirical evidence suggests that EIPS represents good value for money, for example, in Thailand, EIPS delivered an estimated 8:1 return on investment (ROI).5
- Open Access
- 30 January 2024
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 30 (Suppl 2) , s38-s40
Health technology assessment in India in the next decade: reflections on a vision for its path to maturity and impact
Health technology assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle.1 , 2 Its aim is to promote equitable, efficient, high-quality health systems by informing decision-making. Founded in 2017 with the mission to collate and, where needed, generate evidence related to the clinical effectiveness, cost-effectiveness and safety of medicines, devices and health programmes using HTA,3 Health Technology Assessment in India (HTAIn) has since established a network of 18 Regional Resource Centres (RRC) across 13 Indian states and has achieved fundamental milestones to standardise and strengthen HTA methods and processes and embed HTA evidence in decision making (see figure 1).
- 30 January 2024
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 30 (Suppl 2) , s38-s40
Open AccessHealth technology assessment in India in the next decade: reflections on a vision for its path to maturity and impact
Health technology assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle.1 , 2 Its aim is to promote equitable, efficient, high-quality health systems by informing decision-making. Founded in 2017 with the mission to collate and, where needed, generate evidence related to the clinical effectiveness, cost-effectiveness and safety of medicines, devices and health programmes using HTA,3 Health Technology Assessment in India (HTAIn) has since established a network of 18 Regional Resource Centres (RRC) across 13 Indian states and has achieved fundamental milestones to standardise and strengthen HTA methods and processes and embed HTA evidence in decision making (see figure 1).
- Open Access
- 2 August 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (2) , 228-240
Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches
: Little is known about the adverse health, economic, and social impacts of substandard and falsified medicines (SFMs). This systematic review aimed to identify the methods used in studies to measure the impact of SFMs in low- and middle-income countries (LMICs), summarize their findings, and identify gaps in the reviewed literature. A search of eight databases for published papers, and a manual search of references in the relevant literature were conducted using synonyms of SFMs and LMICs. Studies in the English language that estimated the health, social, or economic impacts of SFMs in LMICs published before June 17, 2022 were considered eligible. Search results generated 1,078 articles, and 11 studies were included after screening and quality assessment. All included studies focused on countries in sub-Saharan Africa. Six studies used the Substandard and Falsified Antimalarials Research Impact model to estimate the impact of SFMs. This model is an important contribution. However, it is technically challenging and data demanding, which poses challenges to its adoption by national academics and policymakers alike. The included studies estimate that substandard and falsified antimalarial medicines can account from 10% to ∼40% of total annual malaria costs, and SFMs affect rural and poor populations disproportionately. Evidence on the impact of SFMs is limited in general and nonexistent regarding social outcomes. Further research needs to focus on practical methods that can serve local authorities without major investments in terms of technical capacity and data collection.
- 2 August 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (2) , 228-240
Open AccessHealth, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches
: Little is known about the adverse health, economic, and social impacts of substandard and falsified medicines (SFMs). This systematic review aimed to identify the methods used in studies to measure the impact of SFMs in low- and middle-income countries (LMICs), summarize their findings, and identify gaps in the reviewed literature. A search of eight databases for published papers, and a manual search of references in the relevant literature were conducted using synonyms of SFMs and LMICs. Studies in the English language that estimated the health, social, or economic impacts of SFMs in LMICs published before June 17, 2022 were considered eligible. Search results generated 1,078 articles, and 11 studies were included after screening and quality assessment. All included studies focused on countries in sub-Saharan Africa. Six studies used the Substandard and Falsified Antimalarials Research Impact model to estimate the impact of SFMs. This model is an important contribution. However, it is technically challenging and data demanding, which poses challenges to its adoption by national academics and policymakers alike. The included studies estimate that substandard and falsified antimalarial medicines can account from 10% to ∼40% of total annual malaria costs, and SFMs affect rural and poor populations disproportionately. Evidence on the impact of SFMs is limited in general and nonexistent regarding social outcomes. Further research needs to focus on practical methods that can serve local authorities without major investments in terms of technical capacity and data collection.
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S139
EE435 Value for Money of Post-Market Surveillance of Medicines: Evidence from Indonesia
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S139
EE435 Value for Money of Post-Market Surveillance of Medicines: Evidence from Indonesia
- Top Cited Papers
- 5 May 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (6) , 1120-1124
Patient reported outcome assessment must be inclusive and equitable
- 5 May 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (6) , 1120-1124
Top Cited PapersPatient reported outcome assessment must be inclusive and equitable
- Open Access
- 13 April 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (4) , e003923
A systematic examination of international funding flows for Ebola virus and Zika virus outbreaks 2014–2019: donors, recipients and funding purposes
Introduction There has been no systematic comparison of how the policy response to past infectious disease outbreaks and epidemics was funded. This study aims to collate and analyse funding for the Ebola epidemic and Zika outbreak between 2014 and 2019 in order to understand the shortcomings in funding reporting and suggest improvements. Methods Data were collected via a literature review and analysis of financial reporting databases, including both amounts donated and received. Funding information from three financial databases was analysed: Institute of Health Metrics and Evaluation’s Development Assistance for Health database, the Georgetown Infectious Disease Atlas and the United Nations Financial Tracking Service. A systematic literature search strategy was devised and applied to seven databases: MEDLINE, EMBASE, HMIC, Global Health, Scopus, Web of Science and EconLit. Funding information was extracted from articles meeting the eligibility criteria and measures were taken to avoid double counting. Funding was collated, then amounts and purposes were compared within, and between, data sources. Results Large differences between funding reported by different data sources, and variations in format and methodology, made it difficult to arrive at precise estimates of funding amounts and purpose. Total disbursements reported by the databases ranged from $2.5 to $3.2 billion for Ebola and $150–$180 million for Zika. Total funding reported in the literature is greater than reported in databases, suggesting that databases may either miss funding, or that literature sources overreport. Databases and literature disagreed on the main purpose of funding for socioeconomic recovery versus outbreak response. One of the few consistent findings across data sources and diseases is that the USA was the largest donor. Conclusion Implementation of several recommendations would enable more effective mapping and deployment of outbreak funding for response activities relating to COVID-19 and future epidemics.
- 13 April 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (4) , e003923
Open AccessA systematic examination of international funding flows for Ebola virus and Zika virus outbreaks 2014–2019: donors, recipients and funding purposes
Introduction There has been no systematic comparison of how the policy response to past infectious disease outbreaks and epidemics was funded. This study aims to collate and analyse funding for the Ebola epidemic and Zika outbreak between 2014 and 2019 in order to understand the shortcomings in funding reporting and suggest improvements. Methods Data were collected via a literature review and analysis of financial reporting databases, including both amounts donated and received. Funding information from three financial databases was analysed: Institute of Health Metrics and Evaluation’s Development Assistance for Health database, the Georgetown Infectious Disease Atlas and the United Nations Financial Tracking Service. A systematic literature search strategy was devised and applied to seven databases: MEDLINE, EMBASE, HMIC, Global Health, Scopus, Web of Science and EconLit. Funding information was extracted from articles meeting the eligibility criteria and measures were taken to avoid double counting. Funding was collated, then amounts and purposes were compared within, and between, data sources. Results Large differences between funding reported by different data sources, and variations in format and methodology, made it difficult to arrive at precise estimates of funding amounts and purpose. Total disbursements reported by the databases ranged from $2.5 to $3.2 billion for Ebola and $150–$180 million for Zika. Total funding reported in the literature is greater than reported in databases, suggesting that databases may either miss funding, or that literature sources overreport. Databases and literature disagreed on the main purpose of funding for socioeconomic recovery versus outbreak response. One of the few consistent findings across data sources and diseases is that the USA was the largest donor. Conclusion Implementation of several recommendations would enable more effective mapping and deployment of outbreak funding for response activities relating to COVID-19 and future epidemics.
- Open Access
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6) , 1155-1170
Economics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment
PURPOSE: Cancer is a leading cause of death among children in the Eastern Mediterranean region, where conflict and economic downturn place additional burden on the health sector. In this context, using economic evidence to inform policy decisions is crucial for maximizing health outcomes from available resources. We summarized the available evidence on the economics of pediatric cancer in Jordan, Lebanon, the occupied Palestinian territory, and Turkey. METHODS: A scoping review was performed of seven academic databases and gray literature pertaining to pediatric cancer in the four jurisdictions, published between January 1, 2010, and July 17, 2019. Information was extracted and organized using an analytical framework that synthesizes economic information on four dimensions: the context of the health system, the economics of health care inputs, the economics of service provision, and the economic consequences of disease. RESULTS: Most of the economic evidence available across the four jurisdictions pertains to the availability of health care inputs (ie, drugs, human resources, cancer registration data, and treatment protocols) and individual-level outcomes (either clinical or health-related quality of life). We identified little evidence on the efficiency or quality of health care inputs and of pediatric cancer services. Moreover, we identified no studies examining the cost-effectiveness of any intervention, program, or treatment protocol. Evidence on the economic consequences of pediatric cancer on families and the society at large was predominantly qualitative. CONCLUSION: The available economic evidence on pediatric cancer care in the four countries is limited to resource availability and, to an extent, patient outcomes, with a substantial gap in information on drug quality, service provision efficiency, and cost-effectiveness. Links between researchers and policymakers must be strengthened if pediatric cancer spending decisions, and, ultimately, treatment outcomes, are to improve.
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6) , 1155-1170
Open AccessEconomics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment
PURPOSE: Cancer is a leading cause of death among children in the Eastern Mediterranean region, where conflict and economic downturn place additional burden on the health sector. In this context, using economic evidence to inform policy decisions is crucial for maximizing health outcomes from available resources. We summarized the available evidence on the economics of pediatric cancer in Jordan, Lebanon, the occupied Palestinian territory, and Turkey. METHODS: A scoping review was performed of seven academic databases and gray literature pertaining to pediatric cancer in the four jurisdictions, published between January 1, 2010, and July 17, 2019. Information was extracted and organized using an analytical framework that synthesizes economic information on four dimensions: the context of the health system, the economics of health care inputs, the economics of service provision, and the economic consequences of disease. RESULTS: Most of the economic evidence available across the four jurisdictions pertains to the availability of health care inputs (ie, drugs, human resources, cancer registration data, and treatment protocols) and individual-level outcomes (either clinical or health-related quality of life). We identified little evidence on the efficiency or quality of health care inputs and of pediatric cancer services. Moreover, we identified no studies examining the cost-effectiveness of any intervention, program, or treatment protocol. Evidence on the economic consequences of pediatric cancer on families and the society at large was predominantly qualitative. CONCLUSION: The available economic evidence on pediatric cancer care in the four countries is limited to resource availability and, to an extent, patient outcomes, with a substantial gap in information on drug quality, service provision efficiency, and cost-effectiveness. Links between researchers and policymakers must be strengthened if pediatric cancer spending decisions, and, ultimately, treatment outcomes, are to improve.